Panoramica dell'azienda
Precision BioSciences, Inc. operates as a clinical stage gene editing company dedicated to developing in vivo gene editing therapies designed to perform specific gene edits, including insertion, excision, and elimination within the United States market. The enterprise functions within the Healthcare sector and specifically targets the Biotechnology industry, positioning itself as an entity focused on advanced genomic interventions rather than traditional pharmaceutical manufacturing. The company currently maintains a market capitalization of $172.11M and reports an annual revenue of $34.26M, employing a workforce of 68 individuals to execute its research and development objectives. These valuation and revenue figures indicate that the organization is a mid-sized biotechnology entity with significant headroom for expansion, yet the high multiple of revenue to market cap suggests that the market places substantial value on its intellectual property and pipeline potential rather than current cash generation capabilities.
Salute finanziaria
The company reports a trailing twelve-month revenue of $34.26M against a net income of $-46,609,000 and an EBITDA of $-50,680,000, revealing a substantial gap between top-line growth and bottom-line profitability that points to a heavy cost structure dominated by research and development expenditures. This negative earnings environment results in a free cash flow of $-21,974,250, which signifies that the company is burning cash to fund its operations and is reliant on external capital sources or existing cash reserves to maintain financial flexibility. The margins presented show a gross margin of 100.0%, indicating that the cost of goods sold is negligible relative to sales, while an operating margin of 36.6% suggests efficient overhead management despite the lack of net income. Conversely, a profit margin of -133.4% underscores the significant operating expenses required to bring a gene editing therapy to market before the company can achieve net profitability. On the balance sheet, the firm holds $115.58M in cash against $28.81M in debt, supported by a debt-to-equity ratio of 31.23, which reflects a leverage position where equity is significantly smaller than the debt obligation. Despite the debt presence, a current ratio of 13.32 demonstrates exceptional short-term liquidity, indicating that the company possesses more than thirteen times the current assets necessary to cover its current liabilities. Finally, the return on equity stands at -62.7% and the return on assets at -22.4%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a typical characteristic for clinical-stage biotechnology firms in their development phases.
Valutazione del valore
Valuation multiples for Precision BioSciences, Inc. reflect its pre-profitability status, with a trailing P/E ratio of N/A and a forward P/E of -1.96, implying that the market is pricing the stock based on future earnings expectations that are not yet realized in the trailing twelve months. The price-to-book ratio is recorded at 1.74, suggesting that the market values the company's equity at approximately 1.74 times its book value, which often occurs in biotechnology firms where intangible assets like patents and intellectual property drive value beyond the balance sheet carrying amount. Alternative valuation metrics such as a price-to-sales ratio of 5.02 and an EV/EBITDA of -1.54 provide further context, indicating that investors are willing to pay five dollars for every dollar of revenue generated, betting on future commercialization success rather than current profitability. Price action over the last year shows a 52-week high of $8.82 and a 52-week low of $3.53, meaning the current price sits at a level that requires calculation relative to this range to determine its position within the historical volatility band. The stock exhibits a beta of 1.09, which indicates that the price volatility of DTIL is slightly higher than the broader market, moving 9% more than the market index on average during periods of high correlation.
Growth & Income
Revenue growth stands at an extraordinary 5261.1% year-over-year, while earnings growth is listed as N/A due to the negative net income position, implying that the company is expanding its top line rapidly but has not yet achieved the profitability necessary to demonstrate earnings growth in traditional terms. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is being retained and reinvested into research and development activities rather than distributed to shareholders. This reinvestment strategy is consistent with the company's clinical stage status, where capital allocation is prioritized for advancing its ARCUS genome editing platform and other in vivo therapies. The overall growth and income profile is characterized by explosive revenue expansion and zero dividend distribution, creating a high-risk, high-potential-return scenario typical of early-stage biotechnology companies seeking to commercialize novel gene editing technologies.